NewAmsterdam Pharma Company Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for NewAmsterdam Pharma Company N.V. (NAMS) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-241.60-176.94-22.63-41.79-7.03
Depreciation & Amortization0.110.050.010.010.00
Stock Based Compensation33.6224.574.121.240.00
Change in Working Capital-32.675.8710.374.47-0.65
Change in Accounts Payable-12.955.074.816.561.01
Change in Other Working Capital-15.779.50-12.867.38-1.66
Other Operating Activities81.985.2310.807.380.37
Net Cash from Operating Activities-158.56-141.2210.67-29.51-7.30
Investing Activities
Capital Expenditures-0.67-0.02-0.22-0.02-0.02
Purchases of Investments-62.180.000.000.000.00
Net Cash from Investing Activities-62.85-0.02-0.22-0.02-0.02
Financing Activities
Debt Repayment0.000.00-0.07-0.010.00
Common Stock Issued661.048.91396.9584.700.00
Common Stock Repurchased-0.990.000.000.000.00
Other Financing Activities-0.540.00-5.790.000.00
Net Cash from Financing Activities659.518.91391.9184.7013.85
Summary
Effect of Forex Changes on Cash-6.805.055.25-4.680.00
Net Change in Cash431.29-127.28407.6055.176.56
Cash at Beginning of Period340.45467.7360.139.650.00
Cash at End of Period771.74340.45467.7360.130.00
Free Cash Flow-159.24-141.2410.44-29.54-7.32
Supplemental Disclosures
Interest Paid0.000.000.280.000.00
Income Taxes Paid0.000.030.000.000.00